Novartis AG vs Sprott Uranium Miners ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Sprott Uranium Miners ETF trades at $50.32. The key difference: Novartis AG pays a 3.17% dividend while Sprott Uranium Miners ETF pays none, and Novartis AG is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| NVS | URNM | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $168.62 | $83.99 |
52-Week Low | $113.50 | $44.14 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →